- Home
- NCMI vs FBRX Comparison
NCMI vs FBRX Comparison
Compare NCMI & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCMI | FBRX |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.7M | 366.5M |
| IPO Year | 2006 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NCMI | FBRX |
|---|---|---|
| Price | $3.57 | $30.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $5.90 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 385.7K | 202.2K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | ★ 52.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $2.51 | N/A |
| Revenue Next Year | $11.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.17 | $4.91 |
| 52 Week High | $6.76 | $35.62 |
Technical Indicators
Market Signals| Indicator | NCMI | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 52.86 |
| Support Level | $3.17 | $26.58 |
| Resistance Level | $4.02 | $32.12 |
| Average True Range (ATR) | 0.16 | 2.54 |
| MACD | 0.04 | -0.23 |
| Stochastic Oscillator | 59.85 | 59.35 |
Price Performance
Historical ComparisonAbout NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).